Patent details

300981 Product Name: Doravirine, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout in combinatie met lamivudine, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout, in combinatie met tenofovir of een ester daarvan, in het bijzonder een disoproxil ester, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout, in het bijzonder een fumaraat zout

The time of generation of the report may vary depending on the number of the selected files and the pages of each file. If the generation of the consolidated PDF file takes long, you may reduce the number of selected files and proceed with the generation of the PDF in batches.
You have not selected any documents

Basic Information

Publication number:
300981
Type:
Certificate
SPC Type:
Medical
Basic Patent Number:
EP2924034
Status:
Application Pending
Application number:
300981
Procedural language:
Dutch
First Applicant Residence Country:
Canada (CA)

Marketing Authorization

Marketing Authorization Number:
EU/1/18/1333/001-002
Marketing Authorization Type:
EEA
Marketing Authorization Date:
26/11/2018
Marketing Authorization Country:
European Union (EU)

Dates

Filing date:
16/04/2019
First Marketing Authorization date:
26/11/2018
Grant date:
Activation date:
Lapsed By Non Payment Annual Fee Date:
Renunciation Date:
NullificationDate:
Registration date:
17/04/2019
SPC/SPC Extension Expiration Date:
Lapsed By Expiration Date:
Withdrawal date:
Revocation Date:
Invalidity Date:
Withdrawal Market Authorization Date:
Refusal Date:

Applicant/holder

From:
17/04/2019
 
 

 

Name:
Merck Canada Inc.
Address:
16711 Trans-Canada Highway, KIRKLAND, QC H9H 3L1, Canada (CA)

Agent

1

Name:
dr. R.C. van Duijvenbode c.s.
From:
07/11/2025
Address:
NLO Postbus 29720, 2502 LS, Den Haag, Netherlands (NL)
To:

2

Name:
ir. M.F.J.M. Ketelaars c.s.
From:
17/04/2019
Address:
NLO Postbus 29720, 2502 LS, Den Haag, Netherlands (NL)
To:
07/11/2025

Publication

Bulletin

Bulletin Heading:
SPC
Journal edition number:
17/19
Publication date:
24/04/2019
Description:
Applications and granted Supplementary Protection Certificates (or the extensions of the Supplementary Protection Certificates)
Filing date Document type Document Description Number of pages File Type
18/04/2019 Outgoing Correspondence Confirmation receipt request 1 PDF /3/6/0/0/0/0800400063/docs/300981_4_267435l174.pdf
16/04/2019 SPC Documents Marketing Authorization SPC 3 PDF /3/6/0/0/0/0800400063/docs/300981_0_supplprotectioncertificate20190417114532202.pdf
16/04/2019 SPC Documents Annex SPC 1 PDF /3/6/0/0/0/0800400063/docs/300981_1_supplprotectioncertificate20200608030023056.pdf
16/04/2019 SPC Documents Summary of the characteristics of the product 29 PDF /3/6/0/0/0/0800400063/docs/300981_2_supplprotectioncertificate20190417114532285.pdf
16/04/2019 SPC Documents Annex SPC 2 PDF /3/6/0/0/0/0800400063/docs/300981_3_supplprotectioncertificate20190417114532369.pdf
16/04/2019 SPC Documents Annex SPC 15 PDF /3/6/0/0/0/0800400063/docs/300981_5_supplprotectioncertificate20190417114532462.pdf
16/04/2019 Application Form First filed application form 2 PDF /3/6/0/0/0/0800400063/docs/300981_6_applicationform20190417114531672.pdf